Understanding Tysabri and Progressive Multifocal Leukoencephalopathy (PML)
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Literacy to Targeted Risk Awareness
If you or a loved one is taking Tysabri (natalizumab) for multiple sclerosis or Crohn's disease, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection. This concern is grounded in decades of pharmacovigilance and regulatory oversight that have shaped how such risks are communicated and managed. This page provides a clear overview of Tysabri-related PML, including FDA safety labeling, risk stratification, and what monitoring involves.
Understanding Tysabri and Its Mechanism of Action
Tysabri (natalizumab) is a monoclonal antibody used primarily in the treatment of multiple sclerosis and Crohn disease. Its mechanism of action involves binding to alpha-4 integrins on the surface of immune cells, thereby preventing their migration across the blood-brain barrier into the central nervous system. While this reduces neuroinflammation in multiple sclerosis, it also impairs normal immune surveillance of the brain. This immunosuppressive effect creates an environment permissive for the reactivation of the JC virus (JCV), a polyomavirus that is typically latent in healthy individuals. When JCV reactivates and infects oligodendrocytes, it causes progressive multifocal leukoencephalopathy (PML), a severe demyelinating disease of the brain. The clinical presentation of PML is variable and often insidious. Patients may develop progressive neurological deficits such as hemiparesis, visual field cuts, cognitive decline, ataxia, and speech disturbances. The diagnosis is typically established through a combination of brain MRI, which shows multifocal, asymmetric white matter lesions without mass effect or contrast enhancement, and detection of JCV DNA in the cerebrospinal fluid by polymerase chain reaction. In some cases, brain biopsy may be required. A retrospective national cohort study of 456 PML patients observed between 1987 and 2024 described the changing clinical and laboratory characteristics of the disease, noting that survival and presentation vary according to the underlying condition (https://pubmed.ncbi.nlm.nih.gov/40922664/).
Regulatory Warnings and Risk Factors for PML
The association between Tysabri and PML is well-documented and carries a boxed warning from the U.S. Food and Drug Administration. The prescribing information states that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three specific risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such indication (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the risk of PML, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This program is designed to ensure that patients are educated about the risks and that prescribers and infusion centers adhere to monitoring protocols. Despite these measures, adverse events continue to be reported. The FDA Adverse Event Reporting System (FAERS) database lists fatigue, multiple sclerosis relapse, headache, gait disturbance, and fall among the most frequently reported events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not specifically quantify PML incidence, they underscore the range of neurological and systemic effects that patients may experience during treatment.
Legal Considerations for Tysabri-Related PML
From a risk perspective, the adequacy of warnings regarding Tysabri and PML is a central consideration. The boxed warning and the TOUCH program represent substantial regulatory efforts to communicate risk. However, questions may arise about whether patients and healthcare providers fully understand the magnitude of risk, particularly in the context of the three identified risk factors. For patients who develop PML, the timeline between exposure and documented harm can vary. PML may occur months to years after initiation of Tysabri, with longer treatment duration being a known risk factor. The latency period complicates the attribution of harm, as patients may have received the drug for extended periods before symptoms emerge. For affected patients and their families, attorney-related considerations may include evaluating whether the warnings provided were adequate and whether the patient's specific risk factors were appropriately assessed and communicated. Legal claims may focus on failure to warn, failure to monitor, or failure to discontinue therapy in a timely manner. Patients who have developed PML after Tysabri treatment may seek legal counsel to explore potential avenues for compensation, particularly if they believe that the risks were not fully explained or that their individual risk profile was not properly managed.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Community Resource & Benefit Desk
Request archival records or inquire about member-exclusive transition and benefit programs.
Frequently Asked Questions
What is Tysabri and how does it cause PML?
Tysabri (natalizumab) is a monoclonal antibody used for multiple sclerosis and Crohn disease. It works by blocking immune cells from entering the brain, which reduces inflammation but also impairs immune surveillance. This allows the JC virus to reactivate and infect brain cells, causing progressive multifocal leukoencephalopathy (PML), a severe demyelinating disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
What are the risk factors for developing PML while on Tysabri?
Diagnosis typically involves brain MRI showing multifocal white matter lesions without contrast enhancement, and detection of JCV DNA in cerebrospinal fluid by PCR. In some cases, brain biopsy may be needed (https://pubmed.ncbi.nlm.nih.gov/40922664/).
What legal options are available for individuals who developed PML after Tysabri?
Patients may pursue legal claims based on failure to warn, failure to monitor, or failure to discontinue therapy. An attorney can evaluate whether the risks were adequately communicated and whether the patient's specific risk factors were properly managed.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Free Case & Eligibility Review
Individuals with documented archive exposure and a related diagnosis may request an independent, no-cost eligibility review.